The 2022 OncoAlert Colloquium DAY 1: Breast Cancer
A warm welcome to the third OncoAlert ColloquiumThis year being held in partnership with: The American Society for Radiation OncologyThe European Cancer Orga…
A warm welcome to the third OncoAlert ColloquiumThis year being held in partnership with: The American Society for Radiation OncologyThe European Cancer Orga…
PURPOSE In the treatment of nonāsmall-cell lung cancer (NSCLC) with a driver mutation, the role of antiāPD-(L)1 antibody after tyrosine kinase inhibitor (TKI) remains unclear.…
Abstract. A majority of cancer patients receive radiation therapy as part of their treatment regimens whether using external beam therapy or locally-delivered radioisotopes. While often…
PLANNING TIMELINE Please review the guidelines on this page, and on the Call for Abstracts document prior to submission. All submitted abstracts (Scientific / ECI…
Approximately 20% to 25% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease (TNM eighth edition).1,2 Every patient should be…
The roster for the 2015 – 2016 Harvard Radiation Oncology Residency Program. Please contact us for more information regarding the program or our residents.
The roster for the 2015 – 2016 Harvard Radiation Oncology Residency Program. Please contact us for more information regarding the program or our residents.
Primary tumor failure is common in patients treated with chemoradiation (CRT) for locally-advanced NSCLC (LA-NSCLC). Stereotactic body radiation therapy (SBRT) yields high rates of primary…
With the expansion of proton radiation therapy centers across the United States and a gradually expanding body of academic evidence supporting its use, more patients…
Tumor hypoxia is a major cause of treatment resistance, especially to radiotherapy at conventional dose rate (CONV), and we wanted to assess whether hā¦
The quiet withdrawal of a 2021 cancer study by Dr. Sam Yoon highlights scientific publishersā lack of transparency around data problems.